SLAMF7 and plasma cell myeloma: In vitro studies have shown that CS1-CAR-NK92 cells and CD138-IFNα-CAR-NK92 cells designed with CS1 and CD138 targets, respectively, successfully inhibited the growth of MM cells and prolonged the survival of myeloma mice [33, 34].